EDTUTC-4 New YorkLog in Sign up

VERX
Vertex, Inc. Class A Common Stock
stockNASDAQ

At CloseOct 2, 2026 3:59:58 PM EDT

12.02USD-2.317%(-0.28)1,397,627

Pre-marketOct 2, 2026 9:14:30 AM EDT

12.29USD-0.081%(-0.01)

After-hoursOct 2, 2026 4:27:30 PM EDT

12.01USD-0.042%(-0.01)

VERX News

Day breaks

10:14 AM EDTAmgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? ·

The Motley Fool

06:11 PM EDTVertex appoints Debanjan Saha to board of directors as Class II director ·

Investing.com

02:57 PM EDTAxsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? ·

The Motley Fool

01:44 PM EDTVertex Expands Disputes Division with Launch of Data Analytics-Focused Practice and Hiring of Matt Ryan ·

PR Newswire

11:21 AM EDTSpectro Cloud Earns FedRAMP Class C Certification for Managing Infrastructure at Scale ·

Business Wire

08:00 AM EDTVertex Appoints DataRobot CEO Debanjan Saha to Board of Directors ·

GlobeNewswire Inc.

09:00 AM EDTMetaview Raises $60M Series C to Lead the Shift to Agentic Recruiting ·

Business Wire

12:13 PM EDTThe Case for Meta Enterprise Platform ·

MBI Deep Dives

05:10 AM EDT2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right. ·

The Motley Fool

10:30 AM EDTUBS raises Vertex stock price target to $615 on kidney drug trial ·

Investing.com

04:01 PM EDT2 Healthcare Stocks That Just Delivered Great News for Investors ·

The Motley Fool

12:53 AM EDTFive Governance Products in 12 Days: The Enterprise AI Control Layer Is Forming, and Dataiku Just Shipped One ·

Forkast News

10:14 AM EDTLilly’s latest China drug deal; Immunovant’s setback in lupus ·

BioPharma Dive

08:42 AM EDTCRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ·

The Motley Fool

02:29 PM EDTVertex Pharma options analysis: heavy put activity signals near-term caution ·

Investing.com

06:14 AM EDTJefferies raises Vertex stock price target on kidney drug data ·

Investing.com

05:25 AM EDTVertex reports results from Phase IIb AMPLIFIED trial for AMKD ·

Clinical Trials Arena

01:39 PM EDTThe Surprise That Sent Vertex — And Its Chief Rival — Soaring ·

Investor's Business Daily

11:24 AM EDTVertex reports positive mid-stage results of inaxaplin for kidney disease ·

Seeking Alpha

11:12 AM EDTBMO reiterates Vertex stock rating on positive trial data ·

Investing.com